New testosterone spray could offer quick fix for low t
NCT ID NCT01894308
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests a new testosterone spray (HypoSpray) in 48 men with low testosterone. Participants receive one of four doses daily for 7 days. The goal is to measure how testosterone levels change and check for skin reactions. Results will guide future, longer studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Testosterone
- What this could lead to
- If successful, this could lead to a more convenient testosterone replacement option for men with low testosterone.
- What could go wrong
- This is a small, early-phase study with only 48 participants and 7 days of treatment. It is designed to find the right dose, not to prove long-term safety or effectiveness. Skin reactions or ineffective dosing are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOGONADOTROPISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Advanced Therapies Centre, The London Clinic
London, NW1 4LJ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.